Advertisement
Research Article| Volume 74, SUPPLEMENT 1, S23-S28, June 30, 2000

Download started.

Ok

The undertreatment of LDL-cholesterol: addressing the challenge

DOI:https://doi.org/10.1016/S0167-5273(99)00108-4
The undertreatment of LDL-cholesterol: addressing the challenge
Previous ArticleThe role of small, dense low density lipoprotein (LDL): a new look

      Abstract

      Patients with dyslipidemia are at increased risk of coronary heart disease (CHD), while treatment to reduce low density lipoprotein cholesterol (LDL-C) concentrations lessens this risk. Consequently, the Lipid Treatment Assessment Project (L-TAP) was undertaken in the US to determine the extent to which primary care practitioners utilize lipid-lowering therapy and to evaluate the success of current therapeutic regimens, using the National Cholesterol Education Program (NCEP) guidelines as therapeutic targets. The L-TAP study, initiated in 1996 and completed in February 1997, recorded LDL-C levels in 4888 patients from 619 US practices. All patients had received lipid-lowering therapy for at least 3 months. The primary care practitioners involved in the study were questioned about the NCEP guidelines and the results confirmed that these physicians were representative of primary care practitioners in the USA. The 4888 patients were categorized according to risk: patients with <2 risk factors (RFs) but no CHD, those with ≥2 RFs but no CHD and patients with confirmed CHD. Overall, only 38% of the patients attained LDL-C target levels or had values lower than these goals. The greater the number of RFs, the lower the proportion of patients achieving target levels. LDL-C targets were less often attained in patients receiving dietary therapy only compared with those receiving lipid lowering drug treatment. However, there was good correlation between the success of treatment and both receipt of and compliance with dietary instruction. In conclusion, a large proportion of dyslipidemic patients who are being treated in primary care are not achieving NCEP target LDL-C levels.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to International Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Frick M.U.
        • Elo O.
        • Haapa K.
        • et al.
        Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia.
        N Engl J Med. 1987; 317: 1237-1245
        View in Article
        • Castelli W.P.
        • Garrison R.J.
        • Wilson P.W.F.
        • Abbott R.D.
        • Kalousdian S.
        • Kannel W.B.
        Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study.
        J Am Med Assoc. 1986; 256: 2835-2838
        View in Article

      3. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. I: reduction in the incidence of coronary heart disease. J Am Med Assoc 1984;251:351–64.

        View in Article
        • Neaton J.D.
        • Blackburn H.
        • Jacobs D.
        • et al.
        Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial.
        Arch Intern Med. 1992; 152: 1490-1500
        View in Article

      5. National Cholesterol Education Program. Report of the NCEP Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults. Arch Intern Med 1988;148:36–69.

        View in Article

      6. National Cholesterol Education Program. Second report of the Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults. Executive summary. Washington, D.C., National Institute of Health, National Heart, Lung and Blood Institute. NIH Publication No. 93-3096, September 1993.

        View in Article

      7. National Heart, Lung and Blood Institute. Cholesterol lowering in the patient with coronary heart disease: physician monograph. Bethesda, M.D., NIH Publication No. 97-3794, September 1997.

        View in Article

      8. The WOSCOPS Study Group. West of Scotland Coronary Prevention Study: Implications for clinical practice. Eur Heart J 1996;17:163–4.

        View in Article
        • Shepherd J.
        • Cobbe S.M.
        • Ford I.
        • et al.
        For the West of Scotland Coronary Prevention Study Group; Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia.
        N Engl J Med. 1995; 333: 1301-1307
        View in Article
        • Sacks F.M.
        • Pfeffer M.A.
        • Moyé L.A.
        • et al.
        For the Cholesterol and Recurrent Events Trial Investigators; The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels.
        New Engl J Med. 1996; 335: 1001-1009
        View in Article

      11. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383–9.

        View in Article

      12. Downs JR, Clearfield, Weis S. et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. J Am Med Assoc 1998;279:1615–22.

        View in Article
        • Schrott H.G.
        • Bittner V.
        • Vittinghoff E.
        • Herrington D.M.
        • Hulley S.
        For the HERS Research Group, Adherence to National Cholesterol Education Program treatment goals in post-menopausal women with heart disease; The Heart and Estrogen/Progestin Replacement Study (HERS).
        J Am Med Assoc. 1997; 277: 1281-1286
        View in Article
        • Schectman G.
        • Hiatt J.
        Drug therapy for hypercholesterolemia in patients with cardiovascular disease: factors limiting achievement of lipid goals.
        Am J Med. 1996; 100: 197-204
        View in Article
        • Marcelino J.J.
        • Feingold K.R.
        Inadequate treatment with UMG-CoA reductase inhibitors by healthcare providers.
        Am J Med. 1996; 100: 605-610
        View in Article

      16. Pearson TA, Kris-Etherton P, Mitchell et al. Improving compliance with step I and step II cholesterol-lowering diets: the rural lipid resource center. Circulation 1995;91:936 (Abstract).

        View in Article
        • Pearson T.A.
        • Laurora I.
        • Chu H.
        • Kafonek S.
        The Lipid Treatment Assessment Project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving NCEP target LDL-C goals.
        Arch Intern Med. 2000; 160: 459-467
        View in Article

      Article info

      Identification

      DOI: https://doi.org/10.1016/S0167-5273(99)00108-4

      Copyright

      © 2000 Elsevier Science Ireland Ltd. Published by Elsevier Inc. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX